TINAGL1 expression in follicular fluid as a biomarker of diminished ovarian reserve

July 15, 2024

A team at Massachusetts General Hospital conducted research to evaluate the expression levels of the extracellular matrix protein tubulointerstitial nephritis antigen-like 1 (TINAGL1) in the human ovary.

BioWorld Science Conferences Biomarkers Genitourinary/sexual function Women's health

Today's news in brief

BioWorld

BioWorld briefs for April 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 10, 2025.

Approved label with medical icons, professional

FDA clears path for Boston Sci’s Bolt IVL to challenge J&J’s Shockwave

BioWorld MedTech

Boston Scientific Corp.’s up to $664 million acquisition of Bolt Medical Inc. closed just days after Bolt secured U.S. FDA 520(k) clearance for its intravascular...

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Remegen’s lupus drug surfaces with phase III myasthenia gravis data

BioWorld

Remegen Co. Ltd. emerged as a surprise challenger in the generalized myasthenia gravis space, unveiling positive phase III data of its China-approved lupus drug,...